HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mark Miglarese Selected Research

Neoplasms (Cancer)

3/2011Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.
10/2008Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
1/2008Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.
8/2007SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mark Miglarese Research Topics

Disease

4Neoplasms (Cancer)
03/2011 - 08/2007
1Hepatocellular Carcinoma (Hepatoma)
02/2012

Drug/Important Bio-Agent (IBA)

2ErbB Receptors (EGF Receptor)IBA
10/2008 - 01/2008
1Somatomedin Receptors (Somatomedin Receptor)IBA
02/2012
13- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA
02/2012
1Phosphotransferases (Kinase)IBA
03/2011
1OSI 930IBA
03/2011
1Mechanistic Target of Rapamycin Complex 1IBA
03/2011
1Mechanistic Target of Rapamycin Complex 2IBA
03/2011
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2011
1TOR Serine-Threonine KinasesIBA
03/2011
1IGF Type 1 Receptor (IGF 1 Receptor)IBA
10/2008
1anthranilamideIBA
08/2007
1Protein Kinase InhibitorsIBA
08/2007
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
08/2007